论文部分内容阅读
目的：总结颈内动脉灌注东菱精纯克栓酶（ＤＦ５２１）对发病６小时内的缺血性脑血管病（包括脑血栓及脑栓塞）的治疗效果，并结合文献对溶栓方法及适应证进行评价。材料与方法：为前瞻性研究。对１１例患者行颈内动脉灌注（３例结合血栓抽吸），于６０分钟推注ＤＦ５２１１０ＢＵ后立即复查ＤＳＡ。结果：溶栓１小时再通率８８．９％（８／９）；新鲜血栓再通率１００％（９／９）；临床完全恢复５例，明显好转４例，临床有效率８１．８％（９／１１），ＴＩＡ反复发作者溶栓有效率１００％（５／５）。１例脑血栓溶栓无效，１例高血压脑出血死亡。结论：ＤＦ５２１用于脑缺血早期（血栓形成）动脉溶栓效果良好；对短暂脑缺血反复发作的患者，尽早动脉内溶栓是积极、有效、安全的治疗方法。脑栓塞溶栓效果差，高血压危象应为溶栓禁忌证。
OBJECTIVE: To summarize the curative effect of carotid arterial infusion of DF-521 on ischemic cerebrovascular disease (including cerebral thrombosis and cerebral embolism) within 6 hours of onset, and to review the literature on thrombolysis And indications for evaluation. Materials and Methods: A prospective study. In 11 patients undergoing internal carotid artery perfusion (3 patients with thrombus aspiration), in 60 minutes after DF-52110BU immediate review of DSA. Results: The thrombolysis rate was 88.9% (8/9) after 1 hour; the fresh thrombus recanalization rate was 100% (9/9); 5 cases were clinically completely recovered, 4 cases were significantly improved, and the clinical effective rate was 81.8% (9/11), TIA repeated episodes of thrombolytic efficiency of 100% (5/5). One case of thrombolytic thrombolysis invalid, one case of hypertensive intracerebral hemorrhage died. CONCLUSIONS: DF521 is effective for thrombolysis in early stage of cerebral ischemia (thrombosis). Intravenous thrombolysis as soon as possible in patients with recurrent cerebral ischemia is a positive, effective and safe treatment. Thrombolytic effect of cerebral embolism is poor, hypertensive crisis should be thrombolytic contraindications.